001     258916
005     20230709000347.0
024 7 _ |a 10.1101/2023.06.29.547008
|2 doi
024 7 _ |a altmetric:150789167
|2 altmetric
037 _ _ |a DZNE-2023-00688
100 1 _ |a Blersch, Josephine
|0 P:(DE-2719)9000491
|b 0
|e First author
|u dzne
245 _ _ |a An ex vivo human model for safety assessment of immunotoxicity of engineered nanomaterials
260 _ _ |c 2023
336 7 _ |a Preprint
|b preprint
|m preprint
|0 PUB:(DE-HGF)25
|s 1688650697_17443
|2 PUB:(DE-HGF)
336 7 _ |a WORKING_PAPER
|2 ORCID
336 7 _ |a Electronic Article
|0 28
|2 EndNote
336 7 _ |a preprint
|2 DRIVER
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a Output Types/Working Paper
|2 DataCite
520 _ _ |a The unique physicochemical properties of nanomaterials (NM) and engineered nanomaterials (ENM) have pushed their use in many applications ranging from medicine to the food industry, textiles, and many more fields. Thus, human exposure to NM and ENM is growing by the day. However, the current toxicity tests do not reflect the special characteristics of ENM and are not developed for ENM risk assessment. Here we propose a high-throughput cell-based assay using human peripheral blood mononuclear cells (PBMCs) that can monitor the effects of NM and ENM on cytotoxicity and innate immunity. The proposed assay is fully automated and miniaturized, with excellent assay performance parameters (Z-prime-score >0.5), amenable for large screening campaigns in an industrial setting. Immunotoxicity data for ENM safety assessment are collected in dose-response format. At different states, multiparametric readouts for cytotoxicity, and innate immunity are conducted in a combinatorial method, avoiding ENM-induced bias by endotoxin contamination. Integrating this high-dimensional data allows (i) holistic safety assessment of immunotoxicity effects caused by ENM, classifying safe and toxic ENM phenotypes, and (ii) deconvolving mode of action of the ENM effect on the PBMCs. As added value the data obtained can be used to troubleshoot ENM or for a safe-by-design approach in product development.
536 _ _ |a 899 - ohne Topic (POF4-899)
|0 G:(DE-HGF)POF4-899
|c POF4-899
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef
700 1 _ |a Kurkowsky, Birgit
|0 P:(DE-2719)2810323
|b 1
|u dzne
700 1 _ |a Meyer-Berhorn, Anja
|0 P:(DE-2719)9000668
|b 2
|u dzne
700 1 _ |a Grabowska, Agnieszka Katarzyna
|b 3
700 1 _ |a Feidt, Eva
|b 4
700 1 _ |a Junglas, Ellen
|b 5
700 1 _ |a Roth, Wera
|0 P:(DE-2719)2810635
|b 6
|u dzne
700 1 _ |a Stappert, Dominik
|0 P:(DE-2719)2812160
|b 7
|u dzne
700 1 _ |a Kuebelbeck, Armin
|b 8
700 1 _ |a Denner, Philip
|0 P:(DE-2719)2810245
|b 9
|u dzne
700 1 _ |a Fava, Eugenio
|0 P:(DE-2719)2159508
|b 10
|e Last author
|u dzne
773 _ _ |a 10.1101/2023.06.29.547008
856 4 _ |u https://www.biorxiv.org/content/10.1101/2023.06.29.547008v1
909 C O |o oai:pub.dzne.de:258916
|p VDB
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 0
|6 P:(DE-2719)9000491
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 1
|6 P:(DE-2719)2810323
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 2
|6 P:(DE-2719)9000668
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 6
|6 P:(DE-2719)2810635
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 7
|6 P:(DE-2719)2812160
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 9
|6 P:(DE-2719)2810245
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 10
|6 P:(DE-2719)2159508
913 1 _ |a DE-HGF
|b Programmungebundene Forschung
|l ohne Programm
|1 G:(DE-HGF)POF4-890
|0 G:(DE-HGF)POF4-899
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-800
|4 G:(DE-HGF)POF
|v ohne Topic
|x 0
914 1 _ |y 2023
920 1 _ |0 I:(DE-2719)1040000
|k AG Fava 2 ; AG Fava 2
|l Leitung Core Facilities
|x 0
920 1 _ |0 I:(DE-2719)1040190
|k LAT
|l Laboratory Automation Technologies (LAT)
|x 1
980 _ _ |a preprint
980 _ _ |a VDB
980 _ _ |a I:(DE-2719)1040000
980 _ _ |a I:(DE-2719)1040190
980 _ _ |a UNRESTRICTED


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21